Mesoblast Ltd (MESO)

Mesoblast Stock Analysis & Ratings

MESO Stock Chart & Stats

Day’s Range$3.45 - $3.61
52-Week Range$3.23 - $8.85
Previous Close$3.58
Average Volume (3M)71.93K
Market Cap$456.62M
P/E Ratio-4.6
Next EarningsJun 02, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)-0.76



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Mesoblast’s price range in the past 12 months?
Mesoblast lowest stock price was $3.23 and its highest was $8.85 in the past 12 months.
    What is Mesoblast’s market cap?
    Mesoblast’s market cap is $456.62M.
      What is Mesoblast’s price target?
      The average price target for Mesoblast is $10.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $16.00 ,the lowest forecast is $6.00. The average price target represents 203.99% Increase from the current price of $3.51.
        What do analysts say about Mesoblast?
        Mesoblast’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Mesoblast’s upcoming earnings report date?
          Mesoblast’s upcoming earnings report date is Jun 02, 2022 which is in 10 days.
            How were Mesoblast’s earnings last quarter?
            Mesoblast released its earnings results on Feb 24, 2022. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.203 by $0.003.
              Is Mesoblast overvalued?
              According to Wall Street analysts Mesoblast’s price is currently Undervalued.
                Does Mesoblast pay dividends?
                Mesoblast does not currently pay dividends.
                What is Mesoblast’s EPS estimate?
                Mesoblast’s EPS estimate is -$0.16.
                  How many shares outstanding does Mesoblast have?
                  Mesoblast has 130,090,000 shares outstanding.
                    What happened to Mesoblast’s price movement after its last earnings report?
                    Mesoblast reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.203. Following the earnings report the stock price went up 1.018%.
                      Which hedge fund is a major shareholder of Mesoblast?
                      Currently, no hedge funds are holding shares in MESO


                      Mesoblast Stock Analysis

                      The Mesoblast stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Mesoblast Ltd

                      Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

                      Similar Stocks
                      Price & Change
                      Teva Pharmaceutical

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis